《新股消息》輝煌明天(01351.HK)今日起招股 入場費為2,222.17元
內地移動廣告公司輝煌明天(01351.HK)公布招股詳情,計劃發行1.25億股股份,當中10%在港公開發售,招股價介乎1至1.1元,每手2,000股,入場費為2,222.17元;由今日(28日)至下周一(11月2日)公開招股,預計將於11月11日上市。大有融資為獨家保薦人。
公司是次上市引入2名基石投資者,合共認購3,860萬元股份。以招股價中位數1.05元計,發售所得款項淨額約8,030萬元,當中64.9%將用於擴展集團中介服務;21.3%將用於擴展營銷、客戶服務及設計團隊;10.5%用於提升信息技術及數據管理平台系統;以及餘下3.3%作為一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.